Novo Nordisk and the Next Wave of Weight Loss Drugs The Two-Company Market: Q1 2026 Head to Head Key Numbers Total Revenue: $19.8B (+56% YoY) Adjusted EPS: $8.55 (+156%) Mounjaro: $8.66B (+100%+ YoY) Zepbound: $4.16B (+80% YoY) US Market Share: 60.1% 2026 Guide: $82-85B (raised $2B) Total Revenue: $10.8B (beat estimates) Adjusted EPS: $1.03 (beat) Wegovy: DKK 18.2B (+12% YoY) Wegovy Pill: $354M (doubled estimates) US Market Share: 39.4% 2026 Guide: Adjusted sales decline 4-12% at CER The GLP-1 market in 2026 is a two-company duopoly with a widening gap
NAD+ plays a crucial role in hundreds of processes throughout the body like the production of energy, DNA repair, regulating metabolism, cellular function and repair of your DNA
being the major increase in the GPx enzyme (approximately at 190 %), followed by GST enzyme (approximately at 170 %), GSH (approximately at 160 %), and finally GR enzyme (approximately at 140 %)
516288, ZEN-BIOSCIENCE, China), IL-6 antibodies (dilution 1:50
Why Cycling Matters Receptor desensitization occurs when constant peptide exposure downregulates receptor sensitivity
Cornel JH, Bakris GL, Stevens SR, Alvarsson M, Bax WA, Chuang L-M, et al